TY - JOUR AU - Coles, A. AU - Deans, J. AU - Compston, A. PY - 2004 DA - 2004// TI - Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench JO - Clin Neurol Neurosurg VL - 106 UR - https://doi.org/10.1016/j.clineuro.2004.02.013 DO - 10.1016/j.clineuro.2004.02.013 ID - Coles2004 ER - TY - JOUR AU - Kousin-Ezewu, O. AU - Coles, A. PY - 2013 DA - 2013// TI - Alemtuzumab in multiple sclerosis: latest evidence and clinical prospects JO - Ther Adv Chronic Dis VL - 4 UR - https://doi.org/10.1177/2040622313479137 DO - 10.1177/2040622313479137 ID - Kousin-Ezewu2013 ER - TY - JOUR AU - Cox, A. L. AU - Thompson, S. A. J. AU - Jones, J. L. AU - Robertson, V. H. AU - Hale, G. AU - Waldmann, H. PY - 2005 DA - 2005// TI - Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis JO - Eur J Immunol VL - 35 UR - https://doi.org/10.1002/eji.200535075 DO - 10.1002/eji.200535075 ID - Cox2005 ER - TY - BOOK AU - Cohen, J. A. AU - Coles, A. J. AU - Arnold, D. L. AU - Confavreux, C. AU - Fox, E. J. AU - Hartung, H. -. P. PY - 2012 DA - 2012// TI - Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial ID - Cohen2012 ER - TY - JOUR AU - Coles, A. J. AU - Compston, D. A. S. AU - Selmaj, K. W. AU - Lake, S. L. AU - Moran, S. PY - 2008 DA - 2008// TI - Alemtuzumab vs. interferon beta-1a in early multiple sclerosis JO - N Engl J Med VL - 359 UR - https://doi.org/10.1056/NEJMoa0802670 DO - 10.1056/NEJMoa0802670 ID - Coles2008 ER - TY - BOOK AU - Coles, A. J. AU - Twyman, C. L. AU - Arnold, D. L. AU - Cohen, J. A. AU - Confavreux, C. AU - Fox, E. J. PY - 2012 DA - 2012// TI - Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial ID - Coles2012 ER - TY - JOUR AU - Watanabe, T. AU - Masuyama, J. -. I. AU - Sohma, Y. AU - Inazawa, H. AU - Horie, K. AU - Kojima, K. PY - 2006 DA - 2006// TI - CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells JO - Clin Immunol VL - 120 UR - https://doi.org/10.1016/j.clim.2006.05.006 DO - 10.1016/j.clim.2006.05.006 ID - Watanabe2006 ER - TY - JOUR AU - Xia, M. Q. AU - Tone, M. AU - Packman, L. AU - Hale, G. AU - Waldmann, H. PY - 1991 DA - 1991// TI - Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone JO - Eur J Immunol VL - 21 UR - https://doi.org/10.1002/eji.1830210714 DO - 10.1002/eji.1830210714 ID - Xia1991 ER - TY - JOUR AU - Thomas, K. AU - Eisele, J. C. AU - Rodriguez-Leal, F. A. AU - Hainke, U. AU - Ziemssen, T. PY - 2016 DA - 2016// TI - Acute effects of alemtuzumab infusion in active relapsing remitting multiple sclerosis patients JO - Neurology: Neuroimmunology & Neuroinflammation VL - 3 ID - Thomas2016 ER - TY - STD TI - Willis MD, Harding KE, Pickersgill TP, Wardle M, Pearson OR, Scolding NJ, et al. Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort. Mult Scler. 2015. ID - ref10 ER - TY - JOUR AU - Coles, A. J. AU - Cox, A. AU - Le Page, E. AU - Jones, J. AU - Trip, S. A. AU - Deans, J. PY - 2006 DA - 2006// TI - The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy JO - J Neurol VL - 253 UR - https://doi.org/10.1007/s00415-005-0934-5 DO - 10.1007/s00415-005-0934-5 ID - Coles2006 ER - TY - JOUR AU - Cossburn, M. D. AU - Harding, K. AU - Ingram, G. AU - El-Shanawany, T. AU - Heaps, A. AU - Pickersgill, T. P. PY - 2012 DA - 2012// TI - Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis JO - Neurology VL - 80 UR - https://doi.org/10.1212/WNL.0b013e31827b5927 DO - 10.1212/WNL.0b013e31827b5927 ID - Cossburn2012 ER - TY - STD TI - Freedman MS, Kaplan JM, Markovic-Plese S. Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis. J Clin Cell Immunol. 2013;4. ID - ref13 ER - TY - JOUR AU - Hu, Y. AU - Turner, M. J. AU - Shields, J. AU - Gale, M. S. AU - Hutto, E. AU - Roberts, B. L. PY - 2009 DA - 2009// TI - Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model JO - Immunology VL - 128 UR - https://doi.org/10.1111/j.1365-2567.2009.03115.x DO - 10.1111/j.1365-2567.2009.03115.x ID - Hu2009 ER - TY - JOUR AU - Kousin-Ezewu, O. AU - Parker, R. A. AU - Tuohy, O. AU - Compston, A. AU - Coles, A. AU - Jones, J. PY - 2014 DA - 2014// TI - Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity JO - Neurology VL - 82 UR - https://doi.org/10.1212/WNL.0000000000000520 DO - 10.1212/WNL.0000000000000520 ID - Kousin-Ezewu2014 ER - TY - JOUR AU - Hill-Cawthorne, G. A. AU - Button, T. AU - Tuohy, O. AU - Jones, J. L. AU - May, K. AU - Somerfield, J. PY - 2012 DA - 2012// TI - Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis JO - J Neurol Neurosurg Psychiatr VL - 83 UR - https://doi.org/10.1136/jnnp-2011-300826 DO - 10.1136/jnnp-2011-300826 ID - Hill-Cawthorne2012 ER - TY - JOUR AU - Cossburn, M. AU - Pace, A. A. AU - Jones, J. AU - Ali, R. AU - Ingram, G. AU - Baker, K. PY - 2011 DA - 2011// TI - Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort JO - Neurology VL - 77 UR - https://doi.org/10.1212/WNL.0b013e318228bec5 DO - 10.1212/WNL.0b013e318228bec5 ID - Cossburn2011 ER - TY - JOUR AU - Jones, J. L. AU - Phuah, C. -. L. AU - Cox, A. L. AU - Thompson, S. A. AU - Ban, M. AU - Shawcross, J. PY - 2009 DA - 2009// TI - IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H) JO - J Clin Invest VL - 119 ID - Jones2009 ER - TY - JOUR AU - Harding, K. E. AU - Cossburn, M. AU - Robertson, N. AU - Compston, A. AU - Coles, A. J. AU - Jones, J. L. PY - 2014 DA - 2014// TI - Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis JO - J Neurol Neurosurg Psychiatr VL - 85 UR - https://doi.org/10.1136/jnnp-2014-309236.10 DO - 10.1136/jnnp-2014-309236.10 ID - Harding2014 ER - TY - JOUR AU - Sørensen, P. S. AU - Koch-Henriksen, N. AU - Petersen, T. AU - Ravnborg, M. AU - Oturai, A. AU - Sellebjerg, F. PY - 2014 DA - 2014// TI - Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients JO - J Neurol VL - 261 UR - https://doi.org/10.1007/s00415-014-7325-8 DO - 10.1007/s00415-014-7325-8 ID - Sørensen2014 ER - TY - JOUR AU - Vellinga, M. M. AU - Castelijns, J. A. AU - Barkhof, F. AU - Uitdehaag, B. M. J. AU - Polman, C. H. PY - 2008 DA - 2008// TI - Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients JO - Neurology VL - 70 UR - https://doi.org/10.1212/01.wnl.0000265393.03231.e5 DO - 10.1212/01.wnl.0000265393.03231.e5 ID - Vellinga2008 ER - TY - JOUR AU - La Mantia, L. AU - Prone, V. AU - Marazzi, M. R. AU - Erminio, C. AU - Protti, A. PY - 2014 DA - 2014// TI - Multiple sclerosis rebound after fingolimod discontinuation for lymphopenia JO - Neurol Sci VL - 35 UR - https://doi.org/10.1007/s10072-014-1800-y DO - 10.1007/s10072-014-1800-y ID - La Mantia2014 ER - TY - JOUR AU - Havla, J. B. AU - Pellkofer, H. L. AU - Meinl, I. AU - Gerdes, L. A. AU - Hohlfeld, R. AU - Kümpfel, T. PY - 2012 DA - 2012// TI - Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment JO - Arch Neurol VL - 69 UR - https://doi.org/10.1001/archneurol.2011.1057 DO - 10.1001/archneurol.2011.1057 ID - Havla2012 ER - TY - JOUR AU - Piscolla, E. AU - Hakiki, B. AU - Pasto, L. AU - Razzolini, L. AU - Portaccio, E. AU - Amato, M. P. PY - 2013 DA - 2013// TI - Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient JO - J Neurol VL - 260 UR - https://doi.org/10.1007/s00415-013-6933-z DO - 10.1007/s00415-013-6933-z ID - Piscolla2013 ER - TY - JOUR AU - Sempere, A. P. AU - Berenguer-Ruiz, L. AU - Feliu-Rey, E. PY - 2013 DA - 2013// TI - Rebound of disease activity during pregnancy after withdrawal of fingolimod JO - Eur J Neurol VL - 20 UR - https://doi.org/10.1111/ene.12195 DO - 10.1111/ene.12195 ID - Sempere2013 ER - TY - JOUR AU - Havrdova, E. AU - Horakova, D. AU - Kovarova, I. PY - 2015 DA - 2015// TI - Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use JO - Ther Adv Neurol Disord VL - 8 UR - https://doi.org/10.1177/1756285614563522 DO - 10.1177/1756285614563522 ID - Havrdova2015 ER - TY - JOUR AU - Weber, M. S. AU - Menge, T. AU - Lehmann-Horn, K. AU - Kronsbein, H. C. AU - Zettl, U. AU - Sellner, J. PY - 2012 DA - 2012// TI - Current treatment strategies for multiple sclerosis-efficacy versus neurological adverse effects JO - Curr Pharm Des VL - 18 UR - https://doi.org/10.2174/138161212799040501 DO - 10.2174/138161212799040501 ID - Weber2012 ER - TY - JOUR AU - Plavina, T. AU - Subramanyam, M. AU - Bloomgren, G. AU - Richman, S. AU - Pace, A. AU - Lee, S. PY - 2014 DA - 2014// TI - Anti-JCV antibody levels in serum or plasma further define risk of natalizumab-associated PML JO - Ann Neurol VL - 76 UR - https://doi.org/10.1002/ana.24286 DO - 10.1002/ana.24286 ID - Plavina2014 ER - TY - JOUR AU - Fenu, G. AU - Lorefice, L. AU - Frau, F. AU - Coghe, G. C. AU - Marrosu, M. G. AU - Cocco, E. PY - 2015 DA - 2015// TI - Induction and escalation therapies in multiple sclerosis JO - Antiinflamm Antiallergy Agents Med Chem VL - 14 UR - https://doi.org/10.2174/1871523014666150504122220 DO - 10.2174/1871523014666150504122220 ID - Fenu2015 ER - TY - STD TI - Bayas A, Baum K, Bitsch A, Haas J, Hellwig K, Lang M, et al. One Year Alemtuzumab – What have we Learned in Clinical Practice? Exchange of Experience between Experts on Treatment of Multiple Sclerosis. Akt Neurol. 2015; 42(09):535-41. ID - ref30 ER - TY - JOUR AU - Lublin, F. D. AU - Reingold, S. C. AU - Cohen, J. A. AU - Cutter, G. R. AU - Sørensen, P. S. AU - Thompson, A. J. PY - 2014 DA - 2014// TI - Defining the clinical course of multiple sclerosis: the 2013 revisions JO - Neurology VL - 83 UR - https://doi.org/10.1212/WNL.0000000000000560 DO - 10.1212/WNL.0000000000000560 ID - Lublin2014 ER - TY - JOUR AU - Bermel, R. A. AU - Naismith, R. T. PY - 2015 DA - 2015// TI - Using MRI to make informed clinical decisions in multiple sclerosis care JO - Curr Opin Neurol VL - 28 UR - https://doi.org/10.1097/WCO.0000000000000204 DO - 10.1097/WCO.0000000000000204 ID - Bermel2015 ER - TY - JOUR AU - Ziemssen, T. AU - De Stefano, N. AU - Pia Sormani, M. AU - Van Wijmeersch, B. AU - Wiendl, H. AU - Kieseier, B. C. PY - 2015 DA - 2015// TI - Optimizing therapy early in multiple sclerosis: An evidence-based view JO - Multiple Sclerosis and Related Disorders VL - 4 UR - https://doi.org/10.1016/j.msard.2015.07.007 DO - 10.1016/j.msard.2015.07.007 ID - Ziemssen2015 ER - TY - STD TI - Ziemssen T, Derfuss T, Stefano N, Giovannoni G, Palavra F, Tomic D, et al. Optimizing treatment success in multiple sclerosis. J Neurol. Springer Berlin Heidelberg; 2015;1–15. ID - ref34 ER - TY - JOUR AU - Coles, A. J. AU - Wing, M. AU - Smith, S. AU - Coraddu, F. AU - Greer, S. AU - Taylor, C. PY - 1999 DA - 1999// TI - Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis JO - Lancet VL - 354 UR - https://doi.org/10.1016/S0140-6736(99)02429-0 DO - 10.1016/S0140-6736(99)02429-0 ID - Coles1999 ER - TY - JOUR AU - Leray, E. AU - Yaouanq, J. AU - Le Page, E. AU - Coustans, M. AU - Laplaud, D. AU - Oger, J. PY - 2010 DA - 2010// TI - Evidence for a two-stage disability progression in multiple sclerosis JO - Brain VL - 133 UR - https://doi.org/10.1093/brain/awq076 DO - 10.1093/brain/awq076 ID - Leray2010 ER - TY - JOUR AU - Le Page, E. AU - Deburghgraeve, V. AU - Lester, M. -. A. AU - Cardiet, I. AU - Leray, E. AU - Edan, G. PY - 2015 DA - 2015// TI - Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study JO - J Neurol VL - 262 UR - https://doi.org/10.1007/s00415-015-7653-3 DO - 10.1007/s00415-015-7653-3 ID - Le Page2015 ER - TY - JOUR AU - Rothenbacher, D. AU - Capkun, G. AU - Uenal, H. AU - Tumani, H. AU - Geissbühler, Y. AU - Tilson, H. PY - 2015 DA - 2015// TI - New opportunities of real-world data from clinical routine settings in life-cycle management of drugs: example of an integrative approach in multiple sclerosis JO - Curr Med Res Opin VL - 31 UR - https://doi.org/10.1185/03007995.2015.1027677 DO - 10.1185/03007995.2015.1027677 ID - Rothenbacher2015 ER - TY - JOUR AU - Garnock-Jones, K. P. PY - 2014 DA - 2014// TI - Alemtuzumab: a review of its use in patients with relapsing multiple sclerosis JO - Drugs VL - 74 UR - https://doi.org/10.1007/s40265-014-0195-7 DO - 10.1007/s40265-014-0195-7 ID - Garnock-Jones2014 ER - TY - JOUR AU - Gelfand, J. M. AU - Cotter, J. AU - Klingman, J. AU - Huang, E. J. AU - Cree, B. A. C. PY - 2014 DA - 2014// TI - Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO JO - Neurology: Neuroimmunology & Neuroinflammation VL - 1 ID - Gelfand2014 ER - TY - JOUR AU - Azzopardi, L. AU - Cox, A. L. AU - McCarthy, C. L. AU - Jones, J. L. AU - Coles, A. J. PY - 2015 DA - 2015// TI - Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series JO - J Neurol VL - 263 ID - Azzopardi2015 ER - TY - JOUR AU - Fujihara, K. AU - Nakashima, I. PY - 2014 DA - 2014// TI - Secondary progression and innate immunity in NMO: A possible link to alemtuzumab therapy? JO - Neurology: Neuroimmunology & Neuroinflammation VL - 1 ID - Fujihara2014 ER - TY - JOUR AU - Nali, L. H. D. S. AU - Moraes, L. AU - Fink, M. C. D. AU - Callegaro, D. AU - Romano, C. M. AU - Oliveira ACP, D. PY - 2014 DA - 2014// TI - Natalizumab treatment for multiple sclerosis: updates and considerations for safer treatment in JCV positive patients JO - Arq Neuropsiquiatr VL - 0 ID - Nali2014 ER - TY - JOUR AU - Tuohy, O. AU - Costelloe, L. AU - Bjornson, I. AU - Harding, K. AU - Robertson, N. AU - May, K. PY - 2014 DA - 2014// TI - Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy JO - J Neurol Neurosurg Psychiatr VL - 0 ID - Tuohy2014 ER - TY - JOUR AU - Thomas, K. AU - Ziemssen, T. PY - 2013 DA - 2013// TI - Management of fingolimod in clinical practice JO - Clin Neurol Neurosurg VL - 115 UR - https://doi.org/10.1016/j.clineuro.2013.09.023 DO - 10.1016/j.clineuro.2013.09.023 ID - Thomas2013 ER - TY - JOUR AU - Berger, J. R. AU - Centonze, D. AU - Comi, G. AU - Confavreux, C. AU - Cutter, G. AU - Giovannoni, G. PY - 2010 DA - 2010// TI - Considerations on discontinuing natalizumab for the treatment of multiple sclerosis JO - Ann Neurol VL - 68 UR - https://doi.org/10.1002/ana.22083 DO - 10.1002/ana.22083 ID - Berger2010 ER - TY - JOUR AU - Hauser, S. L. AU - Johnston, S. C. PY - 2009 DA - 2009// TI - Balancing risk and reward: the question of natalizumab JO - Ann Neurol VL - 66 ID - Hauser2009 ER - TY - STD TI - Ziemssen T, Hillert J, Butzkueven H. The importance of collecting structured clinical information on multiple sclerosis. BMC Med. 2016;14:81. ID - ref48 ER - TY - JOUR AU - Diel, R. AU - Hauer, B. AU - Loddenkemper, R. AU - Manger, B. AU - Krüger, K. PY - 2009 DA - 2009// TI - Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases JO - Pneumologie VL - 63 UR - https://doi.org/10.1055/s-0029-1214673 DO - 10.1055/s-0029-1214673 ID - Diel2009 ER - TY - JOUR AU - Caon, C. AU - Namey, M. AU - Meyer, C. AU - Mayer, L. AU - Oyuela, P. AU - Margolin, D. H. PY - 2015 DA - 2015// TI - Prevention and Management of Infusion-Associated Reactions in the Comparison of Alemtuzumab and Rebif ®Efficacy in Multiple Sclerosis (CARE-MS) Program JO - Int J MS Care VL - 17 UR - https://doi.org/10.7224/1537-2073.2014-030 DO - 10.7224/1537-2073.2014-030 ID - Caon2015 ER - TY - JOUR AU - Moreau, T. AU - Coles, A. AU - Wing, M. AU - Isaacs, J. AU - Hale, G. AU - Waldmann, H. PY - 1996 DA - 1996// TI - Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis JO - Brain VL - 119 UR - https://doi.org/10.1093/brain/119.1.225 DO - 10.1093/brain/119.1.225 ID - Moreau1996 ER - TY - JOUR AU - Wing, M. G. AU - Moreau, T. AU - Greenwood, J. AU - Smith, R. M. AU - Hale, G. AU - Isaacs, J. PY - 1996 DA - 1996// TI - Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells JO - J Clin Invest American Society for Clinical Investigation VL - 98 UR - https://doi.org/10.1172/JCI119110 DO - 10.1172/JCI119110 ID - Wing1996 ER - TY - JOUR AU - Rebello, P. AU - Hale, G. PY - 2002 DA - 2002// TI - Pharmacokinetics of CAMPATH-1H: assay development and validation JO - J Immunol Methods VL - 260 UR - https://doi.org/10.1016/S0022-1759(01)00556-7 DO - 10.1016/S0022-1759(01)00556-7 ID - Rebello2002 ER - TY - BOOK AU - Klotz, L. AU - Berthele, A. AU - Bruck, W. AU - Chan, A. AU - Flachenecker, P. AU - Gold, R. PY - 2016 DA - 2016// TI - Monitoring of blood parameters under course-modified MS therapy: Substance-specific relevance and current recommendations for action PB - Springer Berlin Heidelberg CY - Nervenarzt ID - Klotz2016 ER - TY - STD TI - Tsourdi E, Gruber M, Rauner M, Blankenburg J, Ziemssen T, Hofbauer LC. Graves’ disease after treatment with Alemtuzumab for multiple sclerosis. Hormones (Athens). 2015;14(1):148–53. ID - ref55 ER - TY - JOUR AU - Williams, K. M. AU - Dietzen, D. AU - Hassoun, A. A. AU - Fennoy, I. AU - Bhatia, M. PY - 2014 DA - 2014// TI - Autoimmune thyroid disease following alemtuzumab therapy and hematopoietic cell transplantation in pediatric patients with sickle cell disease JO - Pediatr Blood Cancer VL - 61 UR - https://doi.org/10.1002/pbc.25102 DO - 10.1002/pbc.25102 ID - Williams2014 ER - TY - JOUR AU - Aranha, A. A. AU - Amer, S. AU - Reda, E. S. AU - Broadley, S. A. AU - Davoren, P. M. PY - 2013 DA - 2013// TI - Autoimmune Thyroid Disease in the Use of Alemtuzumab for Multiple Sclerosis: A Review JO - Endocr Pract VL - 11 ID - Aranha2013 ER - TY - JOUR AU - Cuker, A. AU - Coles, A. J. AU - Sullivan, H. AU - Fox, E. AU - Goldberg, M. AU - Oyuela, P. PY - 2011 DA - 2011// TI - A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis JO - Blood VL - 118 UR - https://doi.org/10.1182/blood-2011-08-371138 DO - 10.1182/blood-2011-08-371138 ID - Cuker2011 ER - TY - JOUR AU - Jones, J. L. AU - Coles, A. J. PY - 2014 DA - 2014// TI - Mode of action and clinical studies with alemtuzumab JO - Exp Neurol VL - 262 UR - https://doi.org/10.1016/j.expneurol.2014.04.018 DO - 10.1016/j.expneurol.2014.04.018 ID - Jones2014 ER - TY - JOUR AU - Daniels, G. H. AU - Vladic, A. AU - Brinar, V. AU - Zavalishin, I. AU - Valente, W. AU - Oyuela, P. PY - 2014 DA - 2014// TI - Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients With Relapsing-Remitting Multiple Sclerosis JO - J Clin Endocrinol Metab VL - 99 UR - https://doi.org/10.1210/jc.2013-2201 DO - 10.1210/jc.2013-2201 ID - Daniels2014 ER - TY - JOUR AU - Haase, R. AU - Schultheiss, T. AU - Kempcke, R. AU - Thomas, K. AU - Ziemssen, T. PY - 2012 DA - 2012// TI - Use and acceptance of electronic communication by patients with multiple sclerosis: a multicenter questionnaire study JO - J Med Internet Res VL - 14 UR - https://doi.org/10.2196/jmir.2133 DO - 10.2196/jmir.2133 ID - Haase2012 ER - TY - STD TI - Ziemssen T, Engelmann U, Jahn S, Leptich A, Kern R, Hassoun L, et al. Rationale, Design, and Methods of a Non-interventional Study to Establish Safety, Effectiveness, Quality of Life, Cognition, Health-Related and Work Capacity Data on Alemtuzumab in Multiple Sclerosis Patients in Germany (TREAT-MS). BMC Neurol. 2016. in press. ID - ref62 ER - TY - JOUR AU - Ziemssen, T. AU - Kern, R. AU - Cornelissen, C. PY - 2015 DA - 2015// TI - The PANGAEA study design–a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice JO - BMC Neurol BMC Neurology VL - 18 ID - Ziemssen2015 ER - TY - JOUR AU - Ziemssen, T. AU - Kempcke, R. AU - Eulitz, M. AU - Großmann, L. AU - Suhrbier, A. AU - Thomas, K. PY - 2013 DA - 2013// TI - Multiple sclerosis documentation system (MSDS): moving from documentation to management of MS patients JO - J Neural Transm VL - 120 UR - https://doi.org/10.1007/s00702-013-1041-x DO - 10.1007/s00702-013-1041-x ID - Ziemssen2013 ER - TY - JOUR AU - Rieckmann, P. AU - Boyko, A. AU - Centonze, D. AU - Elovaara, I. AU - Giovannoni, G. AU - Havrdova, E. PY - 2015 DA - 2015// TI - Achieving patient engagement in multiple sclerosis_ A perspective from the multiple sclerosis in the 21st Century Steering Group JO - Multiple Sclerosis and Related Disorders VL - 4 UR - https://doi.org/10.1016/j.msard.2015.02.005 DO - 10.1016/j.msard.2015.02.005 ID - Rieckmann2015 ER - TY - BOOK AU - Schultheiß, T. AU - Kempcke, R. AU - Kratzsch, F. AU - Eulitz, M. AU - Pette, M. AU - Reichmann, H. PY - 2011 DA - 2011// TI - Multiple sclerosis management system 3D: Moving from documentation towards management of patients PB - Springer Berlin Heidelberg CY - Nervenarzt ID - Schultheiß2011 ER - TY - JOUR AU - Rau, D. AU - Lang, M. AU - Harth, A. AU - Naumann, M. AU - Weber, F. AU - Tumani, H. PY - 2015 DA - 2015// TI - Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis--Report of Two Cases JO - IJMS VL - 16 UR - https://doi.org/10.3390/ijms160714669 DO - 10.3390/ijms160714669 ID - Rau2015 ER - TY - JOUR AU - Thomas, K. AU - Dietze, K. AU - Wehner, R. AU - Metz, I. AU - Tumani, H. AU - Schultheiss, T. PY - 2014 DA - 2014// TI - Accumulation and therapeutic modulation of 6-sulfo LacNAc (+) dendritic cells in multiple sclerosis JO - Neurology: Neuroimmunology & Neuroinflammation VL - 1 ID - Thomas2014 ER - TY - JOUR AU - Morrison, V. A. PY - 2014 DA - 2014// TI - Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies JO - Clin Infect Dis VL - 59 UR - https://doi.org/10.1093/cid/ciu592 DO - 10.1093/cid/ciu592 ID - Morrison2014 ER - TY - JOUR AU - Coles, A. J. PY - 2013 DA - 2013// TI - Alemtuzumab therapy for multiple sclerosis JO - Neurotherapeutics VL - 10 UR - https://doi.org/10.1007/s13311-012-0159-0 DO - 10.1007/s13311-012-0159-0 ID - Coles2013 ER - TY - JOUR AU - Safdar, N. AU - Smith, J. AU - Knasinski, V. AU - Sherkow, C. AU - Herrforth, C. AU - Knechtle, S. PY - 2010 DA - 2010// TI - Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study JO - Diagn Microbiol Infect Dis VL - 66 UR - https://doi.org/10.1016/j.diagmicrobio.2009.08.017 DO - 10.1016/j.diagmicrobio.2009.08.017 ID - Safdar2010 ER - TY - JOUR AU - Ibitoye, R. AU - Wilkins, A. PY - 2014 DA - 2014// TI - Thyroid papillary carcinoma after alemtuzumab therapy for MS JO - J Neurol VL - 261 UR - https://doi.org/10.1007/s00415-014-7453-1 DO - 10.1007/s00415-014-7453-1 ID - Ibitoye2014 ER - TY - JOUR AU - Brown, W. AU - Coles, A. PY - 2013 DA - 2013// TI - Alemtuzumab: evidence for its potential in relapsing–remitting multiple sclerosis JO - Drug Des Devel Ther VL - 7 UR - https://doi.org/10.2147/DDDT.S32687 DO - 10.2147/DDDT.S32687 ID - Brown2013 ER - TY - JOUR AU - Coles, A. J. AU - Fox, E. AU - Vladic, A. AU - Gazda, S. K. AU - Brinar, V. AU - Selmaj, K. W. PY - 2012 DA - 2012// TI - Alemtuzumab more effective than interferon-1a at 5-year follow-up of CAMMS223 Clinical Trial JO - Neurology VL - 78 UR - https://doi.org/10.1212/WNL.0b013e31824e8ee7 DO - 10.1212/WNL.0b013e31824e8ee7 ID - Coles2012 ER - TY - JOUR AU - McCarthy, C. L. AU - Tuohy, O. AU - Compston, D. A. S. AU - Kumararatne, D. S. AU - Coles, A. J. AU - Jones, J. L. PY - 2013 DA - 2013// TI - Immune competence after alemtuzumab treatment of multiple sclerosis JO - Neurology VL - 81 UR - https://doi.org/10.1212/WNL.0b013e3182a35215 DO - 10.1212/WNL.0b013e3182a35215 ID - McCarthy2013 ER - TY - JOUR AU - Zhang, X. AU - Tao, Y. AU - Chopra, M. AU - Ahn, M. AU - Marcus, K. L. AU - Choudhary, N. PY - 2013 DA - 2013// TI - Differential Reconstitution of T Cell Subsets following Immunodepleting Treatment with Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients with Relapsing-Remitting Multiple Sclerosis JO - J Immunol VL - 191 UR - https://doi.org/10.4049/jimmunol.1301926 DO - 10.4049/jimmunol.1301926 ID - Zhang2013 ER - TY - JOUR AU - Robertson, N. P. AU - Scolding, N. J. PY - 2014 DA - 2014// TI - Immune reconstitution and treatment response in multiple sclerosis following alemtuzumab JO - Neurology VL - 82 UR - https://doi.org/10.1212/WNL.0000000000000530 DO - 10.1212/WNL.0000000000000530 ID - Robertson2014 ER - TY - JOUR AU - Tchao, N. K. AU - Turka, L. A. PY - 2012 DA - 2012// TI - Lymphodepletion and homeostatic proliferation: implications for transplantation JO - Am J Transplant VL - 12 UR - https://doi.org/10.1111/j.1600-6143.2012.04008.x DO - 10.1111/j.1600-6143.2012.04008.x ID - Tchao2012 ER - TY - JOUR AU - Vukusic, S. AU - Marignier, R. PY - 2015 DA - 2015// TI - Multiple sclerosis and pregnancy in the ‘treatment era’ JO - Nat Rev Neurol VL - 11 UR - https://doi.org/10.1038/nrneurol.2015.53 DO - 10.1038/nrneurol.2015.53 ID - Vukusic2015 ER -